Birger Sørensen

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial

Richard B. Pollard, Jürgen K. Rockstroh, Giuseppe Pantaleo et al. · The Lancet Infectious Diseases · 2014 · 108 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

An outbreak of group B meningococcal disease: tracing the causative strain of Neisseria meningitidis by DNA fingerprinting

Bjørn‐Erik Kristiansen, Birger Sørensen, Bjarne Bjorvatn et al. · Journal of Clinical Microbiology · 1986 · 56 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

Anne‐Marte Bakken Kran, Birger Sørensen, Jørgen Nyhus et al. · AIDS · 2004 · 49 citations

Life Sciences, Immunology, Infectious Diseases +17

Phase I Trial of a Therapeutic HIV Type 1 Vaccine, Vacc-4x, in HIV Type 1-Infected Individuals with or without Antiretroviral Therapy

Birgitta Åsjö, Helen Stavang, Birger Sørensen et al. · AIDS Research and Human Retroviruses · 2002 · 42 citations

Veterinary Medicine, Immunology, Infectious Diseases +17

A novel peptide-based vaccine candidate with protective efficacy against influenza A in a mouse model

José Herrera-Rodriguez, Tjarko Meijerhof, Hubert G.M. Niesters et al. · Virology · 2017 · 41 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17